Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep 25:3:256.
doi: 10.3389/fonc.2013.00256.

Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research

Affiliations
Review

Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research

Nuzhat Ahmed et al. Front Oncol. .

Abstract

More than one third of ovarian cancer patients present with ascites at diagnosis, and almost all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread of ovarian cancer and is associated with poor disease prognosis. Malignant ascites acts as a reservoir of a complex mixture of soluble factors and cellular components which provide a pro-inflammatory and tumor-promoting microenvironment for the tumor cells. Subpopulations of these tumor cells exhibit cancer stem-like phenotypes, possess enhanced resistance to therapies and the capacity for distal metastatic spread and recurrent disease. Thus, ascites-derived malignant cells and the ascites microenvironment represent a major source of morbidity and mortality for ovarian cancer patients. This review focuses on recent advances in our understanding of the molecular, cellular, and functional characteristics of the cellular populations within ascites and discusses their contributions to ovarian cancer metastasis, chemoresistance, and recurrence. We highlight in particular recent translational findings which have used primary ascites-derived tumor cells as a tool to understand the pathogenesis of the disease, yielding new insights and targets for therapeutic manipulation.

Keywords: ascites; chemoresistance; cytokines; metastasis; ovarian carcinoma; recurrence.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol (2010) 177(3):1053–6410.2353/ajpath.2010.100105 - DOI - PMC - PubMed
    1. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 13(4):273–8210.1038/nrc3432 - DOI - PMC - PubMed
    1. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol (2007) 18(5):945–910.1093/annonc/mdl499 - DOI - PubMed
    1. Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer (2005) 92(8):1475–8510.1038/sj.bjc.6602495 - DOI - PMC - PubMed
    1. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol (2003) 201(2):229–3710.1002/path.1441 - DOI - PubMed